Wearable pumps and subcutaneous delivery: a new frontier in heart failure management

By Kevin Robinson | Published: 15-May-2026
Drug Delivery

Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing

You need to be a subscriber to read this article.
Click here to find out more.

Results from the SUBCUT HF II trial, presented at the European Society of Cardiology Heart Failure Congress 2026 in Barcelona, have demonstrated that wearable subcutaneous drug delivery can safely replace prolonged intravenous therapy for patients with worsening heart failure.

Led by researchers at the University of Glasgow, the study enrolled 172 patients across 20 UK hospitals, with participants on the device arm discharged from hospital an average of 5 days earlier than standard care (after approximately 2 days of inpatient monitoring rather than the typical 9–10).

At the centre of the innovation is a skin-friendly subcutaneous formulation of furosemide, paired with a wearable mini-pump developed by SQ Innovation Inc. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A new dimension in drug manufacturing

Read more
The FDA approval of the first 3D printed drug for public use signals changes ahead for the pharma manufacturing sector

Trending Articles

  1. Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Inhaled therapies advance as clinical trial data signal progress on two respiratory fronts Two separate clinical programmes have reported encouraging progress in the development of inhaled therapies for respiratory conditions, with positive data emerging from trials targeting viral infection prevention and cystic fibrosis (CF)
  3. Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
  4. Hovione enters partnership with Ripple Therapeutics The move is set to expand the use of Ripple's Epidel platform beyond ophthalmic applications
  5. Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A new dimension in drug manufacturing

The FDA approval of the first 3D printed drug for public use signals changes ahead for the pharma manufacturing sector
Drug Delivery

embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio

US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
Manufacturing

Lonza expands AAV offering with Xcite AAV stable Producer Cell Line platform to idustrialise Viral Vector Manufacturing

New technology demonstrates superior performance versus transient transfection in clinically relevant customer gene of interest and engineered capsid, enabling scalable and cost-effective AAV manufacturing. Launch reflects Lonza’s deep expertise in cell line development, viral vector manufacturing, and platform industrialisation built over decades of supporting complex biologics
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Addressing Project Optimus with the Net Treatment Benefit framework

Aligned with the US FDA's Project Optimus initiative, the Net Treatment Benefit framework offers an integrated approach to dose optimisation that balances efficacy, safety and tolerability across multiple prioritised outcomes. Dr Kevin Robinson (KSR) spoke to Pascal Piedbois (PP) to find out more
You need to be a subscriber to read this article.
Click here to find out more.
Drug Delivery

Inhaled therapies advance as clinical trial data signal progress on two respiratory fronts

Two separate clinical programmes have reported encouraging progress in the development of inhaled therapies for respiratory conditions, with positive data emerging from trials targeting viral infection prevention and cystic fibrosis (CF)
Drug Delivery

Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships

Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Subscribe now